MARLBOROUGH, Mass. (AP) ¿ Drugmaker Sepracor Inc. said Thursday its profit jumped nearly fivefold in the first quarter as a large research and development charge came off its books.

The company, which makes respiratory and central nervous disorder treatments, also recorded a tax benefit and lowered its spending.

Sepracor reported a profit of $35.2 million, or 31 cents per share. Excluding one-time costs and including a tax gains, Sepracor said it earned $96.8 million, or 85 cents per share. Its revenue grew 3 percent, to $330.2 million from $320.8 million.

Analysts polled by Thomson Reuters had forecast a profit of 69 cents per share with $328.6 million in revenue.

Sepracor earned $7.1 million, or 6 cents per share, in the first quarter of 2008. During that quarter, it recorded a research and development charge of $39.2 million after buying the U.S. rights to several respiratory products made by Swiss drugmaker Nycomed.

In the latest quarter, the company also cut general and administrative spending by about $35 million, and pared its research and development spending.

Sepracor maintained its full-year forecasts, predicting an adjusted profit of $2.10 to $2.70 per share and revenue of $1.15 billion to $1.25 billion. Analysts are expecting $2.43 per share and $1.21 billion in revenue.

In morning trading, Sepracor shares picked up 29 cents, or 2 percent, to $14.72.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform